苯环己定
氟哌啶醇
齐拉西酮
氯氮平
药理学
奥氮平
奎硫平
利培酮
精神分裂症(面向对象编程)
NMDA受体
敏化
习惯化
非定型抗精神病薬
心理学
医学
抗精神病药
多巴胺
精神科
神经科学
受体
内科学
作者
Mikhail Kalinichev,Simon T. Bate,Declan N C Jones
标识
DOI:10.1002/0471141755.ph0554s45
摘要
Abstract Presented in this unit is a protocol using subchronically administered phencyclidine (PCP) for establishing a behavioral sensitization model of aspects of schizophrenia. This model is validated using haloperidol and risperidone. The end‐point of the assay is locomotor hyperactivity, which is induced by PCP challenge following subchronic treatment with this NMDA receptor antagonist. The antipsychotics haloperidol, risperidone, and quetiapine all reduce hyperactivity in a dose‐dependent and selective manner. While the effects of other antipsychotics such as clozapine, olanzapine, and ziprasidone are similar to haloperidol, the interpretation of responses to them is often confounded by nonspecific effects during habituation. Curr. Protoc. Pharmacol . 45:5.54.1‐5.54.13. © 2009 by John Wiley & Sons, Inc.
科研通智能强力驱动
Strongly Powered by AbleSci AI